Ascentage Pharma Reports 90% Revenue Surge on Olverembatinib and Lisaftoclax Growth
Event summary
- Ascentage Pharma's 2025 revenue surged 90% YoY to $82.1M, driven by Olverembatinib and Lisaftoclax sales.
- Olverembatinib sales increased 81% YoY to $62.2M, benefiting from NRDL coverage expansion in China.
- Lisaftoclax generated $10.1M in sales in its first five months post-launch.
- Nine Phase III clinical trials are ongoing, including four cleared by FDA and EMA.
- Cash reserves grew 96% YoY to $353.2M, supported by $322.6M in 2025 equity offerings.
The big picture
Ascentage Pharma's strong 2025 performance reflects the growing commercial traction of its oncology portfolio, particularly in China's expanding cancer drug market. The company's ability to navigate regulatory hurdles and convert clinical progress into sustained revenue growth will be critical as it competes with global biopharma players. With nine Phase III trials underway and a robust cash position, Ascentage is positioning itself for potential breakthroughs in key hematologic malignancies.
What we're watching
- Commercial Momentum
- Whether Ascentage can sustain Olverembatinib's 81% growth and expand Lisaftoclax's market penetration beyond China.
- Regulatory Milestones
- The pace at which Phase III trials for Olverembatinib and Lisaftoclax yield positive results, particularly in FDA/EMA-cleared studies.
- Financial Discipline
- How the company balances aggressive R&D spending ($162.7M in 2025) with its path to profitability amid widening losses.
Related topics